anti-CD16/anti-ROR1 bispecific NK-cell engager (VelosBio)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD16/anti-ROR1 bispecific NK-cell engager (VelosBio)
Drug Alias Nameanti-CD16/anti-ROR1 bispecific immune-cell engager (VelosBio)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III agonistsInactive tyrosine-protein kinase transmembrane receptor ROR1 modulators
TargetsLow affinity immunoglobulin gamma Fc region receptor IIIInactive tyrosine-protein kinase transmembrane receptor ROR1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVelosbio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVelosbio IncMerck & Co Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A